MX2021014242A - Uso de linagliptina en terapia antidiabetica cardio- y renoprotectora. - Google Patents

Uso de linagliptina en terapia antidiabetica cardio- y renoprotectora.

Info

Publication number
MX2021014242A
MX2021014242A MX2021014242A MX2021014242A MX2021014242A MX 2021014242 A MX2021014242 A MX 2021014242A MX 2021014242 A MX2021014242 A MX 2021014242A MX 2021014242 A MX2021014242 A MX 2021014242A MX 2021014242 A MX2021014242 A MX 2021014242A
Authority
MX
Mexico
Prior art keywords
cardio
renoprotective
linagliptin
antidiabetic therapy
therapy
Prior art date
Application number
MX2021014242A
Other languages
English (en)
Inventor
Thomas Klein
Eynatten Maximilian Von
Hans-Juergen Woerle
Odd-Erik Johansen
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50277246&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021014242(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2021014242A publication Critical patent/MX2021014242A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

La presente invención se refiere a un determinado inhibidor de DPP-4 para el uso en la terapia cardio- y/o renoprotectora, incluso en pacientes con alto riesgo vascular.
MX2021014242A 2013-03-15 2015-09-02 Uso de linagliptina en terapia antidiabetica cardio- y renoprotectora. MX2021014242A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13159624 2013-03-15
EP13177311 2013-07-19

Publications (1)

Publication Number Publication Date
MX2021014242A true MX2021014242A (es) 2022-01-06

Family

ID=50277246

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015011466A MX2015011466A (es) 2013-03-15 2014-03-14 Uso de linagliptina en terapia antidiabetica cardio-y renoprotectora.
MX2021014242A MX2021014242A (es) 2013-03-15 2015-09-02 Uso de linagliptina en terapia antidiabetica cardio- y renoprotectora.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015011466A MX2015011466A (es) 2013-03-15 2014-03-14 Uso de linagliptina en terapia antidiabetica cardio-y renoprotectora.

Country Status (14)

Country Link
US (8) US20140274889A1 (es)
EP (3) EP3744327A1 (es)
JP (3) JP2016510795A (es)
KR (2) KR20210099201A (es)
CN (2) CN110075098A (es)
AU (2) AU2014230096C1 (es)
BR (1) BR112015020209A2 (es)
CA (1) CA2903577C (es)
CL (1) CL2015002369A1 (es)
EA (1) EA037712B1 (es)
IL (1) IL240064A0 (es)
MX (2) MX2015011466A (es)
PH (1) PH12015502042B1 (es)
WO (1) WO2014140284A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP2540725A1 (de) 2006-05-04 2013-01-02 Boehringer Ingelheim International GmbH Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
JP6034781B2 (ja) 2010-05-05 2016-11-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 併用療法
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
US9968659B2 (en) 2016-03-04 2018-05-15 Novo Nordisk A/S Liraglutide in cardiovascular conditions
CN109152840A (zh) * 2016-03-28 2019-01-04 英特塞普特医药品公司 通过结合fxr激动剂和arb获得的药物
CA3022202A1 (en) * 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
JP2021530510A (ja) * 2018-07-17 2021-11-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 心臓に安全な抗糖尿病療法
MX2021000554A (es) * 2018-07-17 2021-03-29 Boehringer Ingelheim Int Tratamiento antidiabetico cardiovascular y renal seguro.
US20220056014A1 (en) * 2018-12-18 2022-02-24 Wuhan Humanwell Innovative Drug Research and Development Center Limited Company Phenylpyrrolidine compound and use thereof
WO2022244846A1 (ja) * 2021-05-19 2022-11-24 Kagami株式会社 細胞増殖の調整のための組成物及び細胞増殖の調整方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553861B2 (en) * 2005-04-22 2009-06-30 Alantos Pharmaceuticals Holding, Inc. Dipeptidyl peptidase-IV inhibitors
UY32177A (es) * 2008-10-16 2010-05-31 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético
MX2011009852A (es) * 2009-03-27 2011-09-29 Bristol Myers Squibb Co Metodos para prevenir episodios cardiovasculares adversos mayores con inhibidores de dipeptidil peptidasa iv.
NZ599298A (en) * 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
US9034883B2 (en) * 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP2849755A1 (en) * 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174768A1 (en) * 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada

Also Published As

Publication number Publication date
NZ710249A (en) 2021-04-30
EA037712B1 (ru) 2021-05-13
EP2968344A1 (en) 2016-01-20
US20190192523A1 (en) 2019-06-27
CL2015002369A1 (es) 2016-02-19
US20200338086A1 (en) 2020-10-29
US20160089373A1 (en) 2016-03-31
AU2014230096A1 (en) 2015-08-06
US20180263990A1 (en) 2018-09-20
US20170065596A1 (en) 2017-03-09
AU2014230096C1 (en) 2019-08-29
PH12015502042A1 (en) 2016-01-18
AU2014230096B2 (en) 2019-02-21
JP2016510795A (ja) 2016-04-11
EA201500934A1 (ru) 2016-03-31
EP3409279A1 (en) 2018-12-05
EP3744327A1 (en) 2020-12-02
CN105188706A (zh) 2015-12-23
PH12015502042B1 (en) 2016-01-18
KR20210099201A (ko) 2021-08-11
IL240064A0 (en) 2015-09-24
US20210205316A1 (en) 2021-07-08
KR20150128726A (ko) 2015-11-18
BR112015020209A2 (pt) 2017-07-18
CN110075098A (zh) 2019-08-02
WO2014140284A1 (en) 2014-09-18
US20140274889A1 (en) 2014-09-18
JP2019112409A (ja) 2019-07-11
MX2015011466A (es) 2016-01-22
AU2019203445A1 (en) 2019-06-06
US20240033270A1 (en) 2024-02-01
JP2021095409A (ja) 2021-06-24
CA2903577C (en) 2023-10-17
CA2903577A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
PH12015502042A1 (en) Use of linagliptin in cardio-and renoprotective antidiabetic therapy
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
IN2014DN09782A (es)
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
MY187540A (en) Compounds active towards bromodomains
MX2016005556A (es) Compuestos agonistas duales de gip-glp-1 y procedimientos.
IN2015DN01156A (es)
WO2015009726A3 (en) Medical uses of cd38 agonists
PH12016500270A1 (en) Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
CA2908742C (en) Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
PH12015500169A1 (en) Prediction of treatment response to jak/stat inhibitor
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
PH12020550185A1 (en) Semaglutide in medical therapy
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
MX2014012535A (es) Terapia de combinacion de anticuerpos anti-mif y quimioterapeuticos.
WO2014012025A3 (en) Igf-1 proteins and therapeutic uses thereof
MX362111B (es) Un metodo para mejorar la funcion hepatica.
WO2012158776A3 (en) Combination therapy for treatment of cancer
PH12020500472A1 (en) Autotaxin inhibitor compounds
MX2017001512A (es) Compuestos activos hacia bromodominios.
UA79303U (ru) Применение таурина как средства стабилизации концентрации итраконазола в плазме крови при лечении грибковых заболеваний